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a b s t r a c t
Newcastle disease virus (NDV) oncolysis is believed to be facilitated by a defective Type I interferon (IFN)
response. We compared hepatocellular carcinoma (HCC)-derived cell lines and found that TRAIL-
resistant cells were more susceptible to NDV oncolysis than were TRAIL-sensitive cells. In examining
the IFN response, we found that basal expression of the IFN-stimulated gene (ISG)-12a was low in TRAIL-
resistant but high in TRAIL-sensitive cells, and ISG12a over-expression or silencing enhanced or reduced
their TRAIL sensitivities, respectively. Moreover, ISG12a over-expression in TRAIL-resistant cells
decreased NDV replication but surprisingly increased oncolysis while ISG12a silencing had the opposite
effect on TRAIL-sensitive cells. Finally, RIG-I and Noxa appear to also contribute to NDV oncolysis.
Together, these results suggest that high basal ISG12a may inhibit NDV replication and oncolysis, while
low basal ISG12a may allow sufﬁcient NDV replication for induction of ISG12a, and other factors required
for NDV oncolysis, with implications for future therapeutics.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Hepatocellular carcinoma (HCC) is among the main causes of
cancer-related deaths worldwide (Jemal et al., 2011). Only a small
percentage of patients respond to current treatments including
surgery, chemotherapy and radiotherapy. New therapeutic strate-
gies are needed for cancer treatment.
Newcastle disease virus (NDV) is a negative-strand RNA virus
possessing oncolytic activities and has been used as an oncolytic
agent in clinical trials in various human cancers (Shobana et al.,
2013; Zamarin and Palese, 2012). In phase 1 trail, oncolytic strain
of NDV PV701 displays intravenous efﬁcacy. This oncolytic virus
displays a broad spectrum of anti-tumor activity in vitro and
in vivo (Lorence et al., 2007). In another phase I/II trial, intrave-
nous NDV-HUJ (OV001) is well tolerated in recurrent glioblastoma
multiforme (Freeman et al., 2006). Altomonte et al. reported a
novel NDV vector harboring an L289A mutation within the F gene,
which resulted in enhanced fusion and cytotoxicity of hepatocel-
lular carcinoma (HCC) cells in vitro (Altomonte et al., 2010). NDV
has been shown to selectively replicate in cancer cells and damage
them, while sparing normal cells, a property believed to be due to
a defective interferon (IFN) response in cancer cells (Fiola et al.,
2006). Normal cells, which are capable of initiating robust antiviral
responses quickly after infection, can inhibit viral replication
before cell death can be initiated. The sensitivity of NDV to IFN,
coupled with defective IFN signaling pathway in cancer cells,
facilitates NDV replication in the cells and increases their destruc-
tion (Park et al., 2003).
ISG12a (interferon-stimulated gene 12a, interferon alpha-
inducible protein 27) is highly induced by type I IFN in many cell
types (Cheriyath et al., 2011). It has been reported that inhibition
of ISG12a expression prevents the sensitization to etoposide-
induced apoptosis (Rosebeck and Leaman, 2008). Whether ISG12a
is involved in NDV oncolysis is unclear. Many antitumor agents
cause apoptosis of tumor cells and resistance to these agents is due
to antiapoptotic protein overexpression or downregulation of the
proapoptotic proteins (Gyrd-Hansen and Meier, 2011).
NDV exerts its oncolytic activity in infected cells through
apoptosis induction. NDV induces apoptosis through activating
the mitochondrial-dependent pathway (Elankumaran et al., 2006).
For the mitochondria-dependent pathway, oligomerization of Bax
results in the release of cytochrome c and caspase-9 activation.
Activated caspase-3 and caspase-7 provoke cellular destruction by
cleaving several hundred cellular proteins including poly ADP-
ribose polymerase (PARP) (van Gurp et al., 2003). Ectopic expres-
sion of Noxa enhanced viral-induced apoptosis, typiﬁed by
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enhanced cytochrome c release from mitochondrial to the cyto-
solic fraction and increased cleavage of caspases 3 and 9 (Sun and
Leaman, 2005). Self-sacriﬁce of cells limits the spread of infection
and hinders the NDV oncolysis if the virus is present at pretty
low level.
One study demonstrated the enhanced oncolytic activity of
attenuated isolate of NDV (HUJ) undergoing one cycle of replica-
tion in therapy-resistant primary melanoma cells expressing Livin
and the cells have an IFN response (Lazar et al., 2010). A similar
mechanism was suggested in another study which showed
enhanced oncolytic activity of engineered NDV expressing NS1
gene of inﬂuenza A in apoptosis-resistant human non-small-cell
lung cancer cell line overexpressing Bcl-xL (Mansour et al., 2011).
These ﬁndings indicated that the anti-apoptotic effect of anti-
apoptotic proteins might prolong the cancer cell survival and allow
the virus to replicate efﬁciently. Whether selective replication of
NDV in liver cancer cells is due to defective apoptotic signaling or
IFN response will be addressed in the study. A recent study
reported that increased malignancy of cancer cells compared with
less malignant cells correlates with enhanced NDV sensitivity
(Puhlmann et al., 2010). Whether NDV sensitivity correlates with
HCC progression will also be studied in this paper.
To address these questions, we used TRAIL-sensitive well-
differentiated HCC cell lines LH86, HLCZ03 and TRAIL-resistant
advanced HCC cell lines Huh7 and HLCZ01. We demonstrated that
the oncolytic effect of NDV is enhanced in apoptosis-resistant
cancer cells. ISG12a contributes to inhibition of viral replication
and NDV oncolysis in cancer cells through RIG-I. Induction of Noxa
by NDV contributes to ISG12a-mediated oncolysis.
Results
The different sensitivity of HCC cell lines to TRAIL
To better understand the mechanisms of NDV oncolysis, we
have attempted to develop HCC cells using liver tumor tissue
samples. We established a novel HCC cell line HLCZ03. The cells
were derived from well-differentiated HCC tissue of a male
patient. The morphology of HLCZ03 cells is shown in Fig. 1A. The
cells express the human liver-speciﬁc gene and protein albumin
(Fig. 1B and C, respectively).
We examined the TRAIL sensitivity of different human HCC cell
lines LH86, Huh7, HLCZ01 and HLCZ03. The cells were exposed to
TRAIL for 4 h. The cleaved PARP in LH86 and HLCZ03 cells could be
easily detected by western blot (Fig. 1D). Flow cytometry data
showed that well-differentiated LH86 and HLCZ03 cells under-
went apoptosis whereas advanced Huh7 and HLCZ01 cells dis-
played resistance to TRAIL-induced apoptosis (Fig. 1E). We then
tested the cytotoxicity of celecoxib to these HCC cells. Huh7 and
HLCZ01 cells were also resistant to celecoxib compared to LH86
and HLCZ03 cells (Fig. 1F). These results suggested that Huh7 and
HLCZ01 cells might be more resistant to anti-cancer drug-induced
apoptosis.
NDV preferentially induces oncolysis in apoptosis-resistant advanced
cancer cells
Better understanding the mechanisms of NDV oncolysis will
extend our knowledge of this novel anti-tumor strategy and lead
to the successful use of the virus. We used NDV to infect TRAIL-
resistant Huh7 and HLCZ01 cells and sensitive LH86 and HLCZ03
cells and compared the oncolytic activity of NDV in the cells.
Cytotoxicity was measured at 48 h postinfection (pi) by MTS assay.
Despite an apoptotic resistance, we observed stronger oncolytic
activity of NDV in TRAIL-resistant Huh7 and HLCZ01 cells than in
TRAIL-sensitive LH86 and HLCZ03 cells. NDV levels were also
higher in Huh7 and HLCZ01 cells than in LH86 and HLCZ03 cells
(Fig. 2A). The cell cultures were photographed under light micro-
scope at 48 h pi to document the NDV oncolysis in the cells
(Fig. 2B). When we pretreated Huh7 cells with Z-VAD-FMK for 1 h
and infected the cells with NDV, we observed higher oncolytic
activity and enhanced replication of NDV in Huh7 cells pretreated
with Z-VAD-FMK than in non-treated cells (Fig. 2C and D).
To further evaluate the potential oncolytic activity of NDV
in vivo, we tested it in a liver cancer model. Nude mice were
injected with Huh7, HLCZ01, LH86 and HLCZ03 cells to develop
primary tumor. Fourteen days post-tumor implantation, mice
were injected with NDV via i.v. and the control group was injected
with PBS. The data showed that the cytotoxic effect of NDV in
Huh7 and HLCZ01 cell-injected mice was higher than in LH86 and
HLCZ03 cell-injected mice (Fig. 2E). These results indicated that
NDV preferentially infects apoptosis-resistant cells and induces
oncolysis.
NDV overcomes resistance to apoptosis in Cancer cells
As the apoptosis-resistant cells are more susceptible to the
oncolytic activity of NDV, we hypothesized whether resistance of
cancer cells to apoptosis may be responsible for the enhanced viral
replication. To compare apoptosis induction by NDV in Huh7,
HLCZ01, HLCZ03 and LH86 cells, all the cells were infected with
NDV and cleaved PARP was detected by western blot. Cleaved
PARP could be easily detected in Huh7 and HLCZ01 cells at 48 h pi,
and only slightly in LH86 and HLCZ03 cells at 72 h pi (Fig. 3A).
Interestingly, Huh7 and HLCZ01 cells showed an increased cas-
pase-3/7 activity, with a peak at 48 h pi (Fig. 3B). To examine
whether the enhanced caspase-3/7 activity was associated with an
increased number of cells undergoing apoptosis, we examined the
percentage of apoptotic cells using ﬂow cytometry. NDV induced
an increased number of cells undergoing apoptosis in Huh7 and
HLCZ01 cells compared to LH86 and HLCZ03 cells at 48 h pi
(Fig. 3C), suggesting that the increased number of apoptotic
Huh7 and HLCZ01 cells is responsible for the enhanced caspase-
3/7 activity.
ISG12a contributes to TRAIL sensitivity and is induced by NDV
in HCC cells
To identify a possible correlation between ISG12a expression
and HCC progression, ISG12a mRNA levels were determined in
normal tissues (N11–N19), well-differentiated liver tissues (T19–
T25, grades I and II, data not shown), and advanced liver tissues
(T11–T18, grades III and IV, data not shown). There was an inverse
correlation between the basal expression of ISG12a and HCC
progression (Fig. 4A). Our data showed that ISG12a over-
expression in TRAIL-resistant Huh7 cells increased their sensitivity
to TRAIL treatment while ISG12a silencing in TRAIL-sensitive LH86
cells increased their TRAIL resistance (Fig. 4B), indicating that
ISG12a contributes to TRAIL sensitivity. Indeed, the level of
endogenous ISG12a was higher in well-differentiated LH86 and
HLCZ03 cells than in advanced Huh7 and HLCZ01 cells (Fig. 4C).
However, NDV induced higher level of ISG12a in Huh7 and HLCZ01
cells than in LH86 and HLCZ03 cells after 48 h pi (Fig. 4C), which
was coupled with the enhanced NDV oncolysis in Huh7 and
HLCZ01 cells compared to LH86 and HLCZ03 cells (Fig. 2A).
It is possible that NDV preferentially infects and lyses advanced
cancer cells over well-differentiated cancer cells. So we compared
the viral RNA level in different cells. Viral RNA level was higher in
Huh7 and HLCZ01 cells than in LH86 and HLCZ03 cells at late time
points (Fig. 4D). To rule out the possibility that the enhanced NDV
replication in Huh7 and HLCZ01 cells is due to the increased
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cellular permissibility to initial virus inoculation, the cells were
infected with NDV at an MOI of 0.01 and the viral titer was
monitored at 1 and 2 h pi. There was no marked difference of vial
RNA level between these cells at these time points (Fig. 4D). The
data suggested that increased cellular permissibility to initial virus
inoculation is not responsible for the enhanced oncolytic activity
in advanced cancer cells.
NDV infection triggers less innate immune response in Cancer cells
compared to normal primary Human hepatocytes (PHH)
Selective NDV replication in cancer cells has been associated
with a defective innate response in these cells (Fiola et al., 2006).
To examine whether NDV infection induces type I IFN in liver
cancer cells, we used NDV to infect PHH, Huh7, LH86, HLCZ01 and
HLCZ03 cells and compared IFN-β level in these cells. Interestingly,
although the induction of IFN-β was lower in Huh7 and HLCZ01
cells than in LH86 and HLCZ03 cells at early time points, it was
markedly higher in Huh7 and HLCZ01 compared to LH86 and
HLCZ03 after 48 h pi (Fig. 5A). However, cancer cells showed
reduced IFN induction compared with normal primary human
hepatocytes (PHHs) (Fig. 5A). To demonstrate whether IFN pro-
duced inhibits NDV replication, PHH, Huh7 and HLCZ01 cells were
infected with NDV at an MOI of 0.01. The supernatant was
collected 24 h pi and the virus present in the supernatant was
UV inactivated. Naïve Huh7, LH86, HLCZ01 and HLCZ03 cells were
treated with the inactivated supernatant and infected with NDV.
The data demonstrated that supernatant in PHH and cancer cells
inhibited viral replication (Fig. 5B), consistent with predicted
effects of induced IFN. Moreover, cancer cells showed a reduced
response compared with PHH (Fig. 5B). To further examine
whether IFN signaling pathway is functional in the cells, we
treated PHH, Huh7, HLCZ01, LH86 and HLCZ03 cells with recom-
binant IFN-α. Twenty-four hours after treatment, the cells were
infected with NDV. Exogenous IFN inhibited viral replication in
normal and cancer cells (Fig. 5C). There was less IFN response in
cancer cells than that in normal cells (Fig. 5C). To further conﬁrm
that IFN signaling pathway is functional in the cells, we knocked
down IFN receptor in the four cell lines. Downregulation of IFNR
suppressed the antiviral effect of IFN on NDV replication (Fig. 5D).
These results indicate that IFN responsiveness is important to
Fig. 1. Different sensitivity of HCC cells to TRAIL-induced apoptosis. (A) Morphology of HLCZ03 cell line derived from HCC tissues. (B and C) HLCZ03 cells express the human
liver-speciﬁc gene and protein albumin. Total cellular RNA and protein are isolated from CHO, Huh7 and HLCZ03 cells. Albumin mRNA (B) and protein (C) are detected by
RT-PCR and western blot analysis, respectively. CHO and Huh7 are used as negative and positive controls, respectively. (D) The cleaved PARP is detected in cancer cells treated
with TRAIL. Huh7, LH86, HLCZ01 and HLCZ03 cells are treated with TRAIL for 4 h. PARP is detected by western blot. Blots are representative of three independent
experiments. (E) Detection of apoptosis by ﬂow cytometry. Huh7, LH86, HLCZ01 and HLCZ03 cells are treated with TRAIL for 4 h. Samples are analyzed on a FACS Caliber
Cytometer. A minimum of 20,000 events per samples are acquired, and analyzed with CellQuest software. (F) The cleaved PARP is detected in cancer cells treated with
celecoxib. Huh7, LH86, HLCZ01 and HLCZ03 cells are treated with celecoxib for 24 h. PARP is detected by western blot. Blots are representative of three independent
experiments. Results are the average of three independent experiments. nnPo0.01 versus non-treated cells.
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inhibit NDV. All together, NDV infection induces less innate
immune response in cancer cells compare to that in normal
cells.
ISG12a inhibits virus replication and contributes to the oncolytic
effect of NDV in cancer cells
To demonstrate whether ISG12a is a mediator of NDV oncolysis,
we delivered ISG12a into advanced Huh7 and HLCZ01 cells and
analyzed the viral replication and oncolysis of NDV. Forced expres-
sion of ISG12a in Huh7 and HLCZ01 cells was conﬁrmed by western
blot using mouse anti-V5 antibody (Fig. 6A). ISG12a over-expression
in Huh7 and HLCZ01 cells inhibited NDV replication (Fig. 6B).
Surprisingly, NDV oncolysis was higher in Huh7 and HLCZ01 cells
overexpressing ISG12a compared to that in the control cells while
forced expression of ISG12a in Huh7 and HLCZ01 cells had a smaller
effect on cell viability in the absence of viral infection (Fig. 6C).
To further reveal that NDV oncolysis is related to ISG12a, we
knocked down ISG12a in well-differentiated LH86 and HLCZ03
cells and analyzed the viral replication and NDV oncolysis.
As shown in Fig. 6D, ISG12a is knocked down by shRNAs targeting
ISG12a mRNA in LH86 and HLCZ03 cells. ISG12a silencing in LH86
and HLCZ03 cells increased NDV replication (Fig. 6E). In contrast,
the oncolytic effect of NDV was lower in ISG12a shRNA knockdown
LH86 and HLCZ03 cells compared to scrambled-shRNA-transfected
cells (Fig. 6F), supporting the role of ISG12a in NDV oncolysis.
These ﬁndings suggest that ISG12a may inhibit viral replication
and mediate the oncolytic effect of NDV in cancer cells.
RIG-I contributes to ISG12a-mediated inhibition of NDV repli-
cation and oncolysis. RIG-I plays an important role in the innate
immune response to viral infection (Zhu et al., 2007; Wang et al.,
2008; Fournier et al., 2012; Wilden et al., 2009). To identify the
mechanisms of the regulation of viral replication and NDV onco-
lysis by ISG12a, we knocked down RIG-I in LH86 cells using RIG-I
shRNAs. RIG-I was indeed reduced (Fig. 7A). The production of
type I IFN and ISG12a in response to NDV infection was down-
regulated in LH86 cells with RIG-I knockdown (Figs. 7B and C; 8C).
The inhibition of NDV replication by ISG12a in LH86 cells was
partially reversed by RIG-I knockdown (Fig. 7D). In contrast,
silencing of RIG-I in LH86 cells impaired the NDV oncolysis
(Figs. 7E and 8C). Forced expression of ISG12a partially reversed
the decreased NDV oncolysis in RIG-I-silenced cells (Fig. 7F). The
data suggested that RIG-I contributes to ISG12a-mediated inhibi-
tion of NDV replication and oncolysis in cancer cells.
Fig. 2. NDV preferentially induces oncolysis in apoptosis-resistant advanced cancer cells in vitro and in vivo. Huh7, LH86, HLCZ01, and HLCZ03 cells are infected with NDV at
an MOI of 0.02. (A) The percentage of viable cells is determined by MTS assay at 48 h postinfection. The data represent the mean of 3 different experiments performed in at
least triplicate. The level of viral RNA is detected by real-time PCR analysis. ND, not detectable. (B) Cell morphology is documented under light microscopy. (C) Huh7 cells are
pretreated with Z-VAD-FMK and infected by NDV. Cleaved PARP are detected by western blot. (D) Total cellular RNA is isolated and NDV level is detected by real-time PCR.
(E) Nude mice are inoculated subcutaneously with Huh7, HLCZ01, LH86, HLCZ03 cells. Fourteen days post-tumor implantation, the control group is treated with PBS i.v. every
4 days and the other group is treated with NDV (107 PFU/ml in 100 ul). Calculated tumor volumes are plotted against days postinoculation.
N. Liu et al. / Virology 462-463 (2014) 283–294286
Induction of Noxa contributes to ISG12a-mediated oncolysis
To determine the apoptotic pathway involved in NDV oncolysis,
we examined caspase 9 in NDV-infected cells. Cleaved caspase
9 was observed in cells with NDV infection, indicating that NDV
infection activates intrinsic apoptotic pathway (Fig. 8A). Intrinsic
apoptosis is regulated by BH-3 only proteins of Bcl-2 family (Lazar
et al., 2010). NDV infection induced Noxa in cancer cells, although
the level of Puma, Bax, and Bcl-2 did not change (Fig. 8B). Silencing
of ISG12a decreased the expression of Noxa and reduced the
oncolytic effect of NDV (Fig. 8C). Silencing of Noxa by shRNA
inhibited the NDV oncolysis (Fig. 8D). However, forced expression
of Noxa reversed the decreased oncolysis in ISG12a-silenced LH86
cells (Fig. 8E). These data suggested that induction of Noxa by NDV
contributes to ISG12a-mediated oncolysis.
Discussion
Elucidation of the mechanisms of oncolysis of NDV and other
oncolytic viruses will extend our knowledge of the novel anticancer
therapies and lead to clinical use of these viruses (Shobana et al.,
2013; Zaragoza et al., 2006). It had been pointed out that oncolytic
viruses replicate selectively in cancer cells and immortalized cells
because of their defective antiviral response (Wang et al., 2009).
Ours and other recent studies have demonstrated effective onco-
lysis of NDV in cancer cells having an IFN response (Lazar et al.,
2010; Mansour et al., 2011; Puhlmann et al., 2010; Vigil et al., 2007).
The ability of NDV to replicate in IFN-competent cells indicates that
other factors may be responsible for the selectivity.
The absence of innate immune response at early time points
postinfection enhanced NDV replication in advanced cancer cells
and induced high level of ISG12a after 48 h pi, making it a more
efﬁcient oncolytic agent (Figs. 2A and 4C). On the contrary, an early
type I IFN expression inhibited viral replication in well-differentiated
cancer cells (Figs. 4D and 5A), induced low level of ISG12a and less
oncolytic activity of NDV after 48 h (Figs. 2A and 4C). We presume
that the sensitivity of NDV oncolysis in advanced HCC cells may be
dependent on the ability of NDV to induce high level of ISG12a. Our
data showed that ISG12a signiﬁcantly decreased in aggressive
(advanced) cancer tissues, as compared with that of less invasive
(well-differentiated) cancer tissues (Fig. 4A). The oncolytic activity of
NDV was strong in advanced TRAIL-resistant Huh7 and HLCZ01 cells
compared to well-differentiated TRAIL-sensitive LH86 and HLCZ03
cells, corresponding to high induction level of ISG12a in Huh7 and
HLCZ01 after 48 h pi. Forced expression of ISG12a in Huh7 and
HLCZ01 cells inhibited viral RNA replication and enhanced NDV
oncolysis. ISG12a silencing in LH86 and HLCZ03 cells increased NDV
replication but inhibited oncolytic effect of NDV. All the data suggest
that ISG12a expression may be responsible for the oncolytic effect
of NDV.
The oncolytic activity of NDV in cancer cells possessing resis-
tance to TRAIL-mediated apoptosis was partially still mediated
through apoptosis. However, apoptosis induced by NDV infection
was much earlier in Huh7 and HLCZ01 cells than in LH86 and
HLCZ03 cells. The early apoptosis in Huh7 and HLCZ01 cells may be
due to the induction of high ISG12a level and the activation of
various apoptosis pathways by NDV infection. The early induction of
IFN by NDV in well-differentiated LH86 and HLCZ03 cells inhibited
viral replication and delayed apoptosis and oncolysis of the cells.
Due to low level of endogenous ISG12a, activation of antiviral
response may be deﬁcient in Huh7 and HLCZ01 during early virus
infection, allowing increased viral replication and subsequent IFN
production, which would explain the higher level of IFN and ISG12a
in the cells at late time points. When IFN generation is delayed and
ISG12a is highly induced in advanced Huh7 and HLCZ01 cells, virus
replication progresses too far to be effectively inhibited by IFN and
ISG12a at later time points after infection, even with higher level of
Fig. 3. NDV overcomes resistance to apoptosis in cancer cells. (A) Cleaved PARP detected by western blot. Huh7, LH86, HLCZ01 and HLCZ03 cells are infected with NDV at an
MOI of 0.02. Cell lysates are analyzed by western blotting with monoclonal anti-PARP antibody. Blots are representative of ﬁve independent experiments. (B) Caspase-3/7
activity in NDV-infected cancer cells. Huh7, LH86, HLCZ01 and HLCZ03 cells are infected with NDV at an MOI of 0.02. The cells are collected and caspase-3/7 activity is
measured at indicated time points. Caspase-3/7 activity is presented as relative ﬂuorescence units and normalized to non-infected cells. (C) Huh7, LH86, HLCZ01 and HLCZ03
cells are infected with NDV at an MOI of 0.02. The cells are analyzed by ﬂow cytometry.
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type I IFN and ISG12a in Huh7 and HLCZ01 cells compared to LH86
and HLCZ03 cells (Fig. 5A). These data indicated that early induction
of IFN rather than high level of IFN at later stage is important for
resistant to NDV infection, which is consistent with one recent
report (Wilden et al., 2011).
Apoptosis is one of the intracellular innate immune responses
to viral infection (Smith et al., 2013; Cary et al., 2011). Many tumor
cells have developed various strategies to inhibit apoptosis trig-
gered by NDV infection. We proposed that the oncolytic speciﬁcity
of NDV may be secondary to high level of ISG12a induced by NDV
in cancer cells. After initial virus entry, the property of apoptosis
resistance prolongs the cancer cells during early viral infection,
producing more virus particles and inducing high level of ISG12a,
causing enhanced NDV oncolysis in the cells.
The selective oncolysis of virus may be due to the deﬁcient IFN
system in the cells, while robust innate immune in normal cells
prevents viral replication (Huang et al., 2012). However, our data
demonstrated that IFN signaling pathway is partially functional in
cancer cells compared to that of normal cells, as evidenced by
induction of IFN by NDV in cancer cells although at a lower level
than in normal cells, and by inhibition of NDV replication in cancer
cells by pretreatment with recombinant IFN. The ability of NDV to
induce IFN may be an additional beneﬁt for its oncolytic activity.
Anticancer properties of IFN are established by its stimulated
genes or through regulating innate and adaptive immunity
(Matsumura et al., 2005; Smyth, 2005). Our overall data suggest
that high basal level of ISG12a in TRAIL-sensitive cells may inhibit
NDV replication and oncolysis, while low basal level of ISG12a in
TRAIL-resistant cells may allow sufﬁcient NDV replication and
oncolysis, and RIG-I and Noxa are required for NDV oncolysis
(Fig. 9).
Our study indicates that NDV may be used for cancer resistant
to therapeutic agents such as TRAIL. Many chemoresistant tumors
have been demonstrated to be related with apoptosis resistance
(Ziebarth et al., 2013; Hu et al., 2012; Goldsmith et al., 2012). NDV
might render the chemoresistant cancer cells sensitive to conven-
tional treatment, as a synergistic effect of oncolytic viruses and
chemotherapeutic drugs (Meng et al., 2012). Our ﬁndings will
provide a clue for the development of oncolytic viral agents
ﬁghting against resistant tumors.
Materials and methods
Cell lines, antibodies, and reagents
Well-differentiated (pathological grade I) HCC cell lines LH86,
HLCZ03 and advanced (pathological grade II, III and IV) HCC cell
Fig. 4. ISG12a contributes to TRAIL sensitivity and is induced by NDV. (A) Quantify of ISG12a mRNA in normal liver tissues, well-differentiated and advanced liver cancer
tissues. Total cellular RNA is isolated from normal liver tissues and liver cancer tissues. ISG12a mRNA is examined by real-time PCR and normalized with GAPDH. The tissues
numbered N11–N19, T11–T18, and T19–T25 represent normal liver tissues, advanced liver cancer tissues, and well-differentiated liver cancer tissues, respectively. (B) ISG12a
mediates TRAIL sensitivity. Forced expression of ISG12a in TRAIL-resistant cells sensitizes the cells to TRAIL treatment (upper). Huh7 cells are transfected by pcDNA3.1-
ISG12a, followed with TRAIL treatment for 4 h. ISG12a and PARP activation is detected by western blot. Knockdown ISG12a renders sensitive cells resistant to TRAIL-induced
apoptosis (lower). LH86 cells are transfected by pSilencer-ISG12a shRNA or pSilencer-control shRNA, followed with TRAIL treatment for 4 h. Silencing of ISG12a is conﬁrmed
by western blot. PARP activation is detected by western blot. (C) ISG12a mRNA level in NDV-infected Huh7, LH86, HLCZ01 and HLCZ03 cells. Huh7, LH86, HLCZ01 and HLCZ03
cells are infected with NDV at an MOI of 0.01 at different time points. ISG12a mRNA is detected by real-time PCR and normalized with GAPDH respectively (upper panel).
Protein is puriﬁed from naïve Huh7, LH86, HLCZ01 and HLCZ03 cells and primary human hepatocytes (PHH1, PHH2) isolated from normal liver tissues of two donors. ISG12a
protein is detected by western blot and quantiﬁed by densitometry in comparison with β-actin (lower panel). (D) Viral RNA level in NDV-infected Huh7, LH86, HLCZ01 and
HLCZ03 cells. Huh7, LH86, HLCZ01 and HLCZ03 cells are infected with NDV at an MOI of 0.01. Intracellular viral RNA is measured by real-time PCR assay at indicated time
points. If not stated otherwise bar graphs represent mean of three independent experiments.
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lines HLCZ01 and Huh7 were maintained in Dulbecco's modiﬁed
Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum (Invitrogen), L-glutamine, nonessential amino
acid (Invitrogen) (Gyrd-Hansen and Meier, 2011; Zhu et al., 2007).
LH86 is a well-differentiated HCC cell line we had established
previously (Zhu et al., 2007). HLCZ01 cells are derived from grade
II differentiated HCC tissue of a male patient (Yang et al., 2014).
Anti-PARP antibody and mouse anti-V5 antibody were obtained
from Cell Signaling Technology and Invitrogen, respectively.
An Annexin V-FITC apoptosis detection kit was purchased from
BD Pharmingen (San Diego, CA). β-actin monoclonal antibody was
from Sigma (St. Louis, MO).
Isolation and establishment of novel hepatoma cell line HLCZ03
The patient signed the consent forms to acknowledge partici-
pation in this study approved by the Review Board of Hunan
Provincial Tumor Hospital. All procedures followed were in
Fig. 5. NDV infection triggers less innate immune response in cancer cells. (A) IFN-β mRNA and protein level in NDV-infected HCC cells and PHH. PHH1 and PHH2 are
isolated from normal liver tissues of two donors. PHH, Huh7, LH86, HLCZ01, and HLCZ03 cells are infected with NDV at an MOI of 0.01. IFN-β mRNA is detected by real-time
PCR and normalized with GAPDH (left panel). Cells are infected and harvested at the indicated time points. IFN-β level in the supernatant is determined by ELISA (right
panel). (B) Antiviral activity in cancer cells with NDV infection. PHH, Huh7 and HLCZ01 cells are infected with NDV at an MOI of 0.01. The supernatant is collected at 24 h pi,
and virus present in the supernatant is UV inactivated. Naïve Huh7, LH86, HLCZ01 and HLCZ03 cells are treated with the inactivated supernatant and then infected with NDV
at an MOI of 0.01. Intracellular viral RNA is detected by real-time PCR. (C) PHH, Huh7, LH86, HLCZ01, and HLCZ03 cells are incubated with 100 U/ml IFN-α. After 24 h of
incubation, cells are washed and infected with NDV at an MOI of 0.01. Total cellular RNA is isolated and NDV RNA level is detected by real-time PCR. (D) IFN receptor (IFNR) is
knocked down by shRNA in Huh7, HLCZ01, LH86, HLCZ03 cells and the cells are infected with NDV at an MOI of 0.01. After 24 h of incubation, cells are washed and incubated
with inactivated supernatant of PHH. Total cellular RNA is isolated and the level of IFNR mRNA and NDV RNA is detected by real-time PCR. If not stated otherwise bar graphs
represent means of three independent experiments. nnPo0.01, nnnPo0.001 versus control cells.
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accordance with the Ethics Committee of Hunan Provincial Tumor
Hospital. HLCZ03 cells were isolated from grade I differentiated
HCC tissue of a male patient. The cells were generated as described
previously (Yang et al., 2014). Brieﬂy, immediately after surgical
resection, the tumor tissue sample was stored in PBS, and
dissociation of the cells was performed within 1 h by two-step
perfusions. Visible vessels were ﬁrst perfused for 15 min with Liver
Perfusion Medium (Invitrogen) to eliminate the blood cells.
A second perfusion was performed with collagenase- and
dispase-containing Liver Digest Medium (Invitrogen) until the
tissue was digested. The perfused tissue was cut into small pieces
and shaken gently in Hepatocytes Wash Medium (Invitrogen). The
cells and small pieces of liver tissue were cultured with DMEM/F12
medium supplemented with 10% FBS. The cell clones were picked
and cultured in 6-well plates. The cells were expanded until cell
growth was sufﬁcient to fulﬁll the culture well. 5106 cells were
injected into NOD/SCID mice. Three months later, tumor tissues
removed from the mouse were cut into small pieces and cultured
with DMEM/F12 medium. One clone was named HLCZ03.
Isolation of primary human hepatocytes (PHH)
The procedures were in accordance with the Ethics Commis-
sion of Hunan Provincial Tumor Hospital. Primary human hepato-
cytes (PHH) were obtained from healthy peritumoral liver
resection specimens from non-HBV, non-HCV and non-HIV
infected patients undergoing partial hepatectomy for primary
hepatocellular carcinoma or secondary metastatic lesions due to
other cancers. PHHs were isolated and cultured as described
previously (Yang et al., 2011).
Fig. 6. ISG12a inhibits viral replication and contributes to the NDV oncolysis in cancer cells. (A) Huh7 and HLCZ01 cells are transfected with pcDNA3.1-ISG12a or control
vector pcDNA3.1. Conﬁrmation of forced expression of ISG12a in Huh7 and HLCZ01 cells by western blot. Blots are representative of three independent experiments. (B) Huh7
and HLCZ01 cells are transfected with pcDNA3.1-ISG12a or control vector pcDNA3.1. The transfected cells are infected with NDV at an MOI of 0.01. The virus titers are
assessed at indicated time points. (C) Oncolysis of NDV is measured by MTS assay. Huh7 and HLCZ01 cells are transfected with pcDNA3.1-ISG12a or control vector pcDNA3.1.
The transfected cells are infected with NDV at an MOI of 0.01. The cell viability is calculated and normalized to the control. (D) LH86 and HLCZ03 cells are transfected with
ISG12a shRNA or scrambled shRNA. Conﬁrmation of ISG12a knockdown by ISG12a shRNA by western blot. Blots are representative of 3 independent experiments. (E) LH86
and HLCZ03 cells are transfected with ISG12a shRNA or scrambled shRNA. The transfected cells are infected with NDV at an MOI of 0.01. The viral titers are assessed at
indicated time points. (F) Oncolysis of NDV measured by MTS assay. LH86 and HLCZ03 cells are transfected with ISG12a shRNA or scrambled shRNA. The transfected cells are
infected with NDV at an MOI of 0.01. The cell viability is calculated and normalized to the control. If not stated otherwise bar graphs represent mean of three independent
experiments. nPo0.05 versus control cells.
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Virus
NDV D817 strain was kindly provided by Joseph Peiris (University
of Hong Kong, Hong Kong). The pellet was suspended in PBS and used
for virus stock. Sucrose density-gradient ultracentrifugation was
performed for puriﬁcation of NDV. Huh7 cells were infected with
NDV at anMOI of 0.01 for 72 h. The supernatant of NDV-infected Huh7
cells was ﬁltered and pelleted through a 35% sucrose cushion at
28,000 rpm in a SW28 rotor (Beckman Coulter) for 16 h at 4 1C. To
remove cytokines or other proteins, the pellet was resuspended in PBS
containing 0.2% EDTA followed by ultracentrifugation at 80,000g for
4 h at 4 1C in a SW41Ti rotor (Beckman Coulter). After resuspension of
the pellet in PBS and determination of viral titer, an aliquot of the virus
stock was frozen at 80 1C.
Tissue samples
A total of 9 snap-frozen normal liver tissues and 15 liver cancer
tissues were collected at Hunan Provincial Tumor Hospital. The human
tissues were obtained and studied in strict adherence to the protocol
approved by Review Board of Hunan Provincial Tumor Hospital.
Construction
ISG12a cDNA was ampliﬁed from total RNA isolated from LH86
cells by standard RT-PCR, and subsequently subcloned into the
expression vector pcDNA3.1/V5-His (Invitrogen). The primers for
ampliﬁcation of ISG12a are 50–CGCGC GGATCCATGGAGGCCT-
CTGCTCTC–30(F), and 50–CTGCAGGAATTCGTAGAACCT CGCAAT-
GA–30(R). The oligonucleotides encoding 19-mer hairpin sequence
speciﬁc to the ISG12a mRNA were incorporated into the pSilencer-
neo plasmid (Ambion). The sequences of ISG12a shRNAs targeting
two regions of ISG12a were 50–AAGTTCATCC TGGGCTCCATT–30 and
50–AATTAACCCGAGCAGGCATGG–30. The plasmids were sequenced,
and transfected into the cells using Lipofectamine 2000 reagent
(Invitrogen). Knockout of ISG12a was conﬁrmed by western blot
and real-time PCR described below.
Titration of infectious virus
Titer of virus stock was calculated by using TCID50 assay prior to
infection. Huh7 cells were seeded in 96-well plates and grown at
37 1C, 5% CO2. After the cells grew to conﬂuence, varying dilutions of
Fig. 7. RIG-I contributes to ISG12a-mediated inhibition of NDV replication and oncolysis. LH86 cells are transfected by pcDNA3.1-RIG-I shRNA or control shRNA. Then the
cells are infected with NDV at an MOI of 0.01 for indicated time periods. (A) Conﬁrmation of RIG-I knockdown by RIG-I shRNA in cancer cells. RIG-I RNA is measured by real-
time PCR and normalized to GAPDH. (B and C) Production of type I IFN and ISG12a in response to NDV infection in cancer cells with RIG-I knockdown. The expression of IFN-β
(B) and ISG12a mRNA (C) is measured by real-time PCR and normalized to GAPDH respectively. (D) Effect of RIG-I knockdown on NDV replication in cancer cells. The viral
RNA is measured by real-time PCR. (E) Effect of RIG-I knockdown on NDV oncolysis in cancer cells. The percentage of viable cells is determined by MTS assay. (F) Forced
expression of ISG12a reversed the decreased NDV oncolysis in RIG-I-silenced LH86 cells. RIG-I-silenced LH86 cells are transfected with pcDNA3.1-ISG12a or control vector
and infected with NDV at an MOI of 0.01. The percentage of viable cells is determined by MTS assay. If not stated otherwise bar graphs represent mean of three independent
experiments. ND, not detectable. nPo0.05, nnPo0.01, nnnPo0.001 versus control cells.
N. Liu et al. / Virology 462-463 (2014) 283–294 291
NDV (10–1–10–10) were added to each well. The plates were then
incubated for three days. The log TCID50/ml calculationwas based on
Reed and Muench formula. We counted cell number and determined
the MOI according to the TCID50 before each experiment.
Viral infection
The cells were plated on 6-well or 96-well plates for 24 h prior
to infection. On the day of infection, the virus was added to the
cells at required MOI. 2 ml of culture medium was added to the
cells and the mixture was incubated at 37 1C. The supernatant was
collected at indicated time points.
Caspase-3/7 assay
The cells were infected with NDV at required MOI in 96-well
plates. Caspase-3/7 activity in the cells was measured using a
Caspase-3/7 assay kit (Promega, Madison, WI) according to the
manual. Caspase-3/7 activity was measured and normalized with
the control.
Flow cytometry analysis
The procedure was described previously (Zhu et al., 2007). The
cells were infected with NDV and analyzed by the Annexin V-FITC
apoptosis detection kit. The data were analyzed with the CellQuest
software.
Animal experiments
Six to seven week old mice (four per group) were inocu-
lated subcutaneously (s.c.) to the mouse ﬂank with HCC cells
Fig. 8. Induction of Noxa contributes to ISG12a-mediated oncolysis. (A) Detection of caspase 9. Huh7 cells are infected with NDV at an MOI of 0.1 for 48 and 72 h. Caspase 9 is
detected by western blot. Blots are representative of ﬁve independent experiments. (B) The cells are treated as described in part A. Noxa, Puma, Bax, and Bcl-2 are detected
by western blot. (C) Silencing of ISG12a decreased Noxa expression and inhibited NDV oncolysis. Huh7 cells are transfected by pcDNA3-ISG12a shRNA or pcDNA3 control
vector, followed with NDV infection at an MOI of 0.01 for 72 h. Noxa and cleaved PARP are detected by western blot. (D) Silencing of Noxa inhibited NDV oncolysis. Huh7 cells
are transfected by pcDNA3-Noxa shRNA or pcDNA3 control vector, followed with NDV infection at an MOI of 0.01 for 72 h. The percentage of viable cells is determined by
MTS assay. The cell viability is calculated and normalized to the control. (E) Huh7 cells are transfected by pcDNA3-ISG12a shRNA or pcDNA3 control vector, followed with
pcDNA3-Noxa transfection. Then the cells are infected with NDV at an MOI of 0.01 for 72 h. PARP is detected by western blot. If not stated otherwise blots are representative
of three independent experiments.
Fig. 9. Role of ISG12a in oncolytic effects of NDV in HCC cells. Our data suggest that
high basal level of ISG12a in TRAIL-sensitive cells may inhibit NDV replication and
oncolysis, while low basal level of ISG12a in TRAIL-resistant cells may allow
sufﬁcient NDV replication and oncolysis, and RIG-I and Noxa are required for
NDV oncolysis.
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(1106 per 0.2 ml) to develop tumor. About 14 days post-tumor
cells implantation, mice were treated either by NDV (107 PFU per
dose) or PBS by i.v. administration every 4 days. Tumor volume
was calculated on the basis of the formula V¼(LW2)/2 (L, length
and W, width).
IFN induction bioassay
The cells were infected with NDV and the supernatant was
collected. Virus in the supernatant was UV inactivated. Huh7 cells
were incubated overnight with the inactivated supernatant. The
supernatant from uninfected cells or cells treated with 100 units of
IFN-α (Roche, Basel, Switzerland) was used as negative or positive
control, respectively. The cells were washed and subsequently
infected with NDV at an MOI of 0.01. The level of NDV and IFN-β
was determined by real-time PCR with NDV and human IFN-β-
speciﬁc primers, respectively. All bioassay experiments were
performed in at least triplicate to conﬁrm the results.
ELISA
The supernatant from viral-infected cells in culture was col-
lected at different times postinfection, and an IFN-β enzyme-
linked immunosorbent assay (ELSIA) kit (PBL Biomedical Labora-
tories) was used to detect IFN-β protein in the supernatant
according to the manufacture's protocol.
MTS assay
The protocol was reported previously (Yang et al., 2013). Brieﬂy,
one day before NDV infection, 1.0103 cells were seeded in
triplicate in a 96-well plate. The cells were cultured with or
without NDV infection at various time points at 37 1C. 20 μl of
the CellTiter AQ Solution containing MTS and an electron coupling
reagent (Promega, Madison, WI) was added to each well. After 2 h
incubation at 37 1C, the absorbance at 490 nm was measured. The
cell viability was calculated with respect to the control samples.
At least three independent experiments were performed.
Western blot analysis
The procedure was published previously (Shi et al., 2014).
Real-time PCR assays
Total cellular RNA was extracted using TRIzol (Invitrogen, Carls-
bad, CA). Superscript II First-Strand Synthesis Kit and Quantitative
PCR SuperMix-UDG were purchased from Invitrogen. The primers
targeting GAPDH had been reported and real-time PCR was per-
formed as described previously (Yang et al., 2014; Shi et al., 2014).
The primers for ISG12, IFN-β, RIG-I and NDV are listed below.
ISG12a: 50–TGCCATGGGCTTCACTGCGG–30 and 50–CTGCCCGAGG-
CAACTCCAC C–30. IFN-β: 50–CAGCAATTTTCAGTGTCAGAAGC–30 and
50–TCATCCTGTCCTT GAGGCAGT–30. RIG-I: 50–CAGAGCACTTGTG-
GACGCTT–30 and 50–TCAGCAACT GAGGTGGCAAT–30. NDV: 50–TCA-
CAGACTCAACTCTTGGG–30 and 50–CAGTATG AGGTGTCAAGTTCTTC–30.
Statistical analysis
The data are presented as means7S.D. The data were analyzed
using two-tailed Student's t-test. nPo0.05, nnPo0.01, nnnPo0.001.
Acknowledgments
This work was supported by National Science and Technology
Major Project of the Ministry of Science and Technology of the
People's Republic of China (2009ZX10004–312), National Natural
Science Foundation of China (81271885), Program for New Century
Excellent Talents in University (NCET-09–0339) and Interdisciplin-
ary Research Project of Hunan University (2014HNDX08) to H.Z.
References
Altomonte, J., Marozin, S., Schmid, R.M., Ebert, O., 2010. Engineered Newcastle
disease virus as an improved oncolytic agent against hepatocellular carcinoma.
Mol. Ther. 18, 275–284.
Cary, Z.D., Willingham, M.C., Lyles, D.S., 2011. Oncolytic vesicular stomatitis virus
induces apoptosis in U87 glioblastoma cells by a type II death receptor
mechanism and induces cell death and tumor clearance in vivo. J. Virol. 85,
5708–5717.
Cheriyath, V., Leaman, D.W., Borden, E.C., 2011. Emerging roles of FAM14 family
members in innate immunity and cancer. J. Interferon Cytokine Res. 31,
173–181.
Elankumaran, S., Rockemann, D., Samal, S.K., 2006. Newcastle disease virus exerts
oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell
death. J. Virol. 80, 7522–7534.
Fiola, C., Peeters, B., Fournier, P., Arnold, A., Bucur, M., Schirrmacher, V., 2006.
Tumor selective replication of Newcastle disease virus: association with defects
of tumor cells in antiviral defence. Int. J. Cancer 119, 328–338.
Fournier, P., Wilden, H., Schirrmacher, V., 2012. Importance of retinoic acid-
inducible gene I and of receptor for type I interferon for cellular resistance to
infection by Newcastle disease virus. Int. J. Oncol. 40, 287–298.
Freeman, A.I., Zakay-Rones, Z., Gomori, J.M., Linetsky, E., Rasooly, L., Greenbaum, E.,
Siegal, T., 2006. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in
recurrent glioblastoma multiforme. Mol. Ther. 13, 221–228.
Goldsmith, K.C., Gross, M., Peirce, S., Luyindula, D., Liu, X., Vu, A., Sliozberg, M.,
Guo, R., Zhao, H., Reynolds, C.P., Hogarty, M.D., 2012. Mitochondrial Bcl-2 family
dynamics deﬁne therapy response and resistance in neuroblastoma. Cancer
Res. 72, 2565–2577.
Gyrd-Hansen, M., Meier, P., 2011. IAPs: from caspase inhibitors to modulators of NF-
kappaB, inﬂammation and cancer. Nat. Rev. Cancer 10, 561–574.
Hu, B., Nandhu, M.S., Sim, H., Agudelo-Garcia, P.A., Saldivar, J.C., Dolan, C.E., Mora,
M.E., Nuovo, G.J., Cole, S.E., Viapiano, M.S., 2012. Fibulin-3 promotes glioma
growth and resistance through a novel paracrine regulation of Notch signaling.
Cancer Res. 72, 3873–3885.
Huang, P.Y., Guo, J.H., Hwang, L.H., 2012. Oncolytic Sindbis virus targets tumors
defective in the interferon response and induces signiﬁcant bystander anti-
tumor immunity in vivo. Mol. Ther. 20, 298–305.
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., 2011. Global cancer
statistics. CA: Cancer J. Clin. 61, 69–90.
Lazar, I., Yaacov, B., Shiloach, T., Eliahoo, E., Kadouri, L., Lotem, M., Perlman, R.,
Zakay-Rones, Z., Panet, A., Ben-Yehuda, D., 2010. The oncolytic activity of
Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells
is dependent on the proapoptotic activity of the inhibitor of apoptosis protein
Livin. J. Virol. 84, 639–646.
Lorence, R.M., Scot Roberts, M., ONeil, J.D., Groene, W.S., Miller, J.A., Mueller, S.N.,
Bamat, M.K., 2007. Phase 1 clinical experience using intravenous administra-
tion of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets 7,
157–167.
Mansour, M., Palese, P., Zamarin, D., 2011. Oncolytic speciﬁcity of Newcastle disease
virus is mediated by selectivity for apoptosis-resistant cells. J. Virol. 85,
6015–6023.
Matsumura, Y., Yashiro, M., Ohira, M., Tabuchi, H., Hirakawa, K., 2005. 5-Fluorouracil
up-regulates interferon pathway gene expression in esophageal cancer cells.
Anticancer Res. 25, 3271–3278.
Meng, S., Zhou, Z., Chen, F., Kong, X., Liu, H., Jiang, K., Liu, W., Hu, M., Zhang, X.,
Ding, C., Wu, Y., 2012. Newcastle disease virus induces apoptosis in cisplatin-
resistant human lung adenocarcinoma A549 cells in vitro and in vivo. Cancer
Lett. 317, 56–64.
Park, M.S., Garcia-Sastre, A., Cros, J.F., Basler, C.R., Palese, P., 2003. Newcastle disease
virus V protein is a determinant of host range restrict. J. Virol. 77, 9522–9532.
Puhlmann, J., Puehler, F., Mumberg, D., Boukamp, P., Beier, R., 2010a. Rac1 is
required for oncolytic NDV replication in human cancer cells and establishes a
link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 29
(15), 2205–2216.
Rosebeck, S., Leaman, D.W., 2008. Mitochondrial localization and pro-apoptotic
effects of the interferon-inducible protein ISG12a. Apoptosis 13, 562–572.
Shi, S., Yu, X., Gao, Y., Xue, B., Wu, X., Wang, X., Yang, D., Zhu, H., 2014. Inhibition of
hepatitis C virus production by aptamer for core protein. J. Virol. 88, 1990–1999.
Shobana, R., Samal, S.K., Elankumaran, S., 2013. Prostate-speciﬁc antigen-retargeted
recombinant Newcastle disease virus for prostate cancer virotherapy. J. Virol.
87, 3792–3800.
Smith, W., Tomasec, P., Aicheler, R., Loewendorf, A., NemčovičováI, I., Wang, E.C.,
Stanton, R.J., 2013. Human cytomegalovirus glycoprotein UL141 targets the
N. Liu et al. / Virology 462-463 (2014) 283–294 293
TRAIL death receptors to thwart host innate antiviral defenses. Cell Host
Microbe. 13, 324–335.
Smyth, M.J., 2005. Type I interferon and cancer immunoediting. Nat. Immunol. 6,
646–648.
Sun, Y., Leaman, D.W., 2005. Involvement of Noxa in cellular apoptotic responses to
IFN, double-stranded RNA and virus infection. J. Biol. Chem. 280, 15561–15568.
van Gurp, M., Festjens, N., van Loo, G., Saelens, X., Vandenabeele, P., 2003.
Mitochondrial intermembrane proteins in cell death. Biochem. Biophys. Res.
Commun. 304, 487–497.
Vigil, A., Park, M.S., Martinez, O., Chua, M.A., Xiao, S., Cros, J.F., Martínez-Sobrido, L.,
Woo, S.L., García-Sastre, A., 2007. Use of reverse genetics to enhance the
oncolytic properties of Newcastle disease virus. Cancer Res. 67, 8285–8292.
Wang, F., Barrett, J.W., Dekaban, G.A., McFadden, G., 2009. Induction of alpha/beta
interferon by myxoma virus is selectively abrogated when primary mouse
embryo ﬁbroblast become immortalized. J. Virol. 83, 5928–5932.
Wang, F., Gao, X., Barrett, J.W., Shao, Q., Bartee, E., Mohamed, M.R., Rahman, M.,
Werden, S., Irvine, T., Gao, J., Dekaban, G.A., McFadden, G., 2008. RIG-I mediates
the co-induction of tumor necrosis factor and type I interferon elicited by
myxoma virus in primary human macrophages. PLoS Pathog. 4, e1000099.
Wilden, H., Fournier, P., Zawatzky, R., Schirrmacher, V., 2009. Expression of RIG-I,
IRF3, IFN-B and IRF7 determines resistance or susceptibility of cells to infection
by Newcastle Disease Virus. Int. J. Oncol. 34, 971–982.
Wilden, H., Schirrmacher, V., Fournier, P., 2011. Important role of interferon
regulatory factor (IRF)-3 in the interferon response of mouse macrophages
upon infection by Newcastle disease virus. Int. J. Oncol. 39, 493–504.
Yang, D., Liu, N., Zuo, C., Lei, S., Wu, X., Zhou, F., Liu, C., Zhu, H., 2011. Innate immune
response of primary human hepatocytes with hepatitis C viral infection. PLoS
One 6, e27552.
Yang, D., Meng, X., Yu, Q., Xu, L., Long, Y., Liu, B., Fang, X., Zhu, H., 2013. Inhibition of
hepatitis C virus infection by DNA aptamer against envelop protein. Antimicrob.
Agents Chemother. 57, 4937–4944.
Yang, D., Zuo, C., Wang, X., Meng, X., Xue, B., Liu, N., Yu, R., Qin, Y., Gao, Y., Wang, Q.,
Hu, J., Wang, L., Zhou, Z., Liu, B., Tan, D., Guang, Y., Zhu, H., 2014. Complete
replication of hepatitis B virus and hepatitis C virus in a newly developed
hepatoma cell line. Proc. Natl. Acad. Sci. U.S.A. 111, E1264–E1273.
Zamarin, D., Palese, P., 2012. Oncolytic Newcastle disease virus for cancer therapy:
old challenges and new directions. Future Microbiol. 7, 347–367.
Zaragoza, C., Saura, M., Padalko, E.Y., Lopez-Rivera, E., Lizarbe, T.R., Lamas, S.,
Lowenstein, C.J., 2006. Viral protease cleavage of inhibitor of kappaBalpha
triggers host cell apoptosis. Proc. Natl. Acad. Sci. U. S. A. 103, 19051–19056.
Zhu, H., Dong, H., Eksioglu, E., Hemming, A., Cao, M., Crawford, J.M., Nelson, D.R.,
Liu, C., 2007. Hepatitis C virus triggers cell death through innate intracellular
antiviral defense system. Gastroenterology 133, 1649–1659.
Ziebarth, A.J., Nowsheen, S., Steg, A.D., Shah, M.M., Katre, A.A., Dobbin, Z.C., Han, H.
D., Lopez-Berestein, G., Sood, A.K., Conner, M., Yang, E.S., Landen, C.N., 2013.
Endoglin (CD105) contributes to platinum resistance and is a target for tumor-
speciﬁc therapy in epithelial ovarian cancer. Clin. Cancer Res. 19, 170–182.
N. Liu et al. / Virology 462-463 (2014) 283–294294
